|
1
|
Sun L, Wen L, Li Q, Chen R, Wen S, Lai X, Lai Z, Cao J, Zhang Z, Hao M, Cao F, Sun S. Microbial Fermentation Enhances the Effect of Black Tea on Hyperlipidemia by Mediating Bile Acid Metabolism and Remodeling Intestinal Microbes. Nutrients 2024; 16:998. [PMID: 38613030 PMCID: PMC11013065 DOI: 10.3390/nu16070998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Revised: 03/22/2024] [Accepted: 03/26/2024] [Indexed: 04/14/2024] Open
Abstract
Black tea (BT), the most consumed tea worldwide, can alleviate hyperlipidemia which is a serious threat to human health. However, the quality of summer BT is poor. It was improved by microbial fermentation in a previous study, but whether it affects hypolipidemic activity is unknown. Therefore, we compared the hypolipidemic activity of BT and microbially fermented black tea (EFT). The results demonstrated that BT inhibited weight gain and improved lipid and total bile acid (TBA) levels, and microbial fermentation reinforced this activity. Mechanistically, both BT and EFT mediate bile acid circulation to relieve hyperlipidemia. In addition, BT and EFT improve dyslipidemia by modifying the gut microbiota. Specifically, the increase in Lactobacillus johnsonii by BT, and the increase in Mucispirillum and Colidextribacter by EFT may also be potential causes for alleviation of hyperlipidemia. In summary, we demonstrated that microbial fermentation strengthened the hypolipidemic activity of BT and increased the added value of BT.
Collapse
Affiliation(s)
- Lingli Sun
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Lianghua Wen
- College of Horticulture, South China Agricultural University, Guangzhou 510000, China; (L.W.); (F.C.)
| | - Qiuhua Li
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Ruohong Chen
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Shuai Wen
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Xingfei Lai
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Zhaoxiang Lai
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Junxi Cao
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Zhenbiao Zhang
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Mengjiao Hao
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| | - Fanrong Cao
- College of Horticulture, South China Agricultural University, Guangzhou 510000, China; (L.W.); (F.C.)
| | - Shili Sun
- Tea Research Institute, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China; (L.S.); (Q.L.); (R.C.); (S.W.); (X.L.); (Z.L.); (J.C.); (Z.Z.); (M.H.)
| |
Collapse
|
|
2
|
Su X, Gao Y, Yang R. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity. Front Immunol 2023; 14:1127743. [PMID: 37256134 PMCID: PMC10225537 DOI: 10.3389/fimmu.2023.1127743] [Citation(s) in RCA: 17] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 03/07/2023] [Indexed: 06/01/2023] Open
Abstract
Bile acids (BAs) as cholesterol-derived molecules play an essential role in some physiological processes such as nutrient absorption, glucose homeostasis and regulation of energy expenditure. They are synthesized in the liver as primary BAs such as cholic acid (CA), chenodeoxycholic acid (CDCA) and conjugated forms. A variety of secondary BAs such as deoxycholic acid (DCA) and lithocholic acid (LCA) and their derivatives is synthesized in the intestine through the involvement of various microorganisms. In addition to essential physiological functions, BAs and their metabolites are also involved in the differentiation and functions of innate and adaptive immune cells such as macrophages (Macs), dendritic cells (DCs), myeloid derived suppressive cells (MDSCs), regulatory T cells (Treg), Breg cells, T helper (Th)17 cells, CD4 Th1 and Th2 cells, CD8 cells, B cells and NKT cells. Dysregulation of the BAs and their metabolites also affects development of some diseases such as inflammatory bowel diseases. We here summarize recent advances in how BAs and their metabolites maintain gut and systemic homeostasis, including the metabolism of the BAs and their derivatives, the role of BAs and their metabolites in the differentiation and function of immune cells, and the effects of BAs and their metabolites on immune-associated disorders.
Collapse
Affiliation(s)
- Xiaomin Su
- Translational Medicine Institute, Affiliated Tianjin Union Medical Center of Nankai University, Nankai University, Tianjin, China
- State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China
- Department of Immunology, Nankai University School of Medicine, Nankai University, Tianjin, China
| | - Yunhuan Gao
- Translational Medicine Institute, Affiliated Tianjin Union Medical Center of Nankai University, Nankai University, Tianjin, China
- State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China
- Department of Immunology, Nankai University School of Medicine, Nankai University, Tianjin, China
| | - Rongcun Yang
- Translational Medicine Institute, Affiliated Tianjin Union Medical Center of Nankai University, Nankai University, Tianjin, China
- State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China
- Department of Immunology, Nankai University School of Medicine, Nankai University, Tianjin, China
| |
Collapse
|
|
3
|
Zhang XL, Chen L, Yang J, Zhao SS, Jin S, Ao N, Yang J, Liu HX, Du J. Vitamin D alleviates non-alcoholic fatty liver disease via restoring gut microbiota and metabolism. Front Microbiol 2023; 14:1117644. [PMID: 36819064 PMCID: PMC9932697 DOI: 10.3389/fmicb.2023.1117644] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 01/10/2023] [Indexed: 02/05/2023] Open
Abstract
Background Non-alcoholic fatty liver disease (NAFLD) represents a severe public health problem. Dysbiosis of gut microbiome has been identified as one of the key environmental factors contributing to NAFLD. As an essential nutrition, Vitamin D (VD) plays an important role in regulating gut microbiota based on its receptor (Vitamin D Receptor, VDR) which is highly expressed in the gastrointestinal tract. Methods Rats were fed with HFD (high-fat diet) for 12 weeks. And the rats were treated with VD two times a week by intraperitoneal injection for 12 weeks. H&E staining combined with plasma biochemical index was performed to characterize pathological changes and function of the liver. Fecal microbiota 16S rRNA gene sequencing and metabolomics were taken to reveal the altered gut microbiota and metabolites. Result The VD alleviates the HFD-induced lipid accumulation in the liver as well as decreases the levels of amlodipine besylate (ALT) and amlodipine aspartate (AST). VD supplement decreased the ratio of phylum Firmicutes/Bacteroidetes (F/B) but increased alpha diversity. In addition, the VD treatment improved the HFD-induced gut microbiota by increasing the Prevotella and Porphyromonadaceae and decreasing Mucispirillum, Acetatifactor, Desulfovibrio, and Oscillospira abundance. Furthermore, the capability of tyrosine metabolism, tryptophan metabolism, arginine biosynthesis, and sphingolipid metabolism was enhanced after VD treatment. Consistently, Prevotella positively correlated with tryptophan metabolism and sphingolipid metabolism. Importantly, the Prevotella abundance was positively associated with serotonin, melatonin, tryptamine, L-arginine, and 3-dehydrosphinganine which synthesize from tryptophan, tyrosine, arginosuccinate, and serine, respectively. Conclusion VD treatment inhibited HFD-induced NAFLD accompany by dysbiosis gut microbiota and metabolites, suggesting that VD supplement could be a potential intervention used for NAFLD treatment by targeting the specific microbiota.
Collapse
Affiliation(s)
- Xiao-Lei Zhang
- Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
| | - Lei Chen
- Institute of Health Sciences, China Medical University, Shenyang, Liaoning, China,Institute of Life Sciences, China Medical University, Shenyang, Liaoning, China,Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning, China
| | - Jiang Yang
- Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
| | - Shan-Shan Zhao
- Institute of Health Sciences, China Medical University, Shenyang, Liaoning, China,Institute of Life Sciences, China Medical University, Shenyang, Liaoning, China,Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning, China
| | - Shi Jin
- Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
| | - Na Ao
- Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
| | - Jing Yang
- Institute of Health Sciences, China Medical University, Shenyang, Liaoning, China,Institute of Life Sciences, China Medical University, Shenyang, Liaoning, China,Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning, China
| | - Hui-Xin Liu
- Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China,Institute of Health Sciences, China Medical University, Shenyang, Liaoning, China,Institute of Life Sciences, China Medical University, Shenyang, Liaoning, China,Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning, China,*Correspondence: Hui-Xin Liu,
| | - Jian Du
- Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China,Jian Du,
| |
Collapse
|
|
4
|
Zhao SS, Chen L, Yang J, Wu ZH, Wang XY, Zhang Q, Liu WJ, Liu HX. Altered Gut Microbial Profile Accompanied by Abnormal Fatty Acid Metabolism Activity Exacerbates Endometrial Cancer Progression. Microbiol Spectr 2022; 10:e0261222. [PMID: 36227107 PMCID: PMC9769730 DOI: 10.1128/spectrum.02612-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Accepted: 09/16/2022] [Indexed: 01/07/2023] Open
Abstract
Endometrial cancer (EC) is the most prevalent gynecological malignancy, with a higher risk in obese woman, indicating the possibility of gut microbiota involvement in EC progression. However, no direct evidence of a relationship between EC and gut microbiota in humans has been discovered. Here, we performed 16S rRNA sequencing to explore the relationship between dysbiosis of gut microbiota and cancer development in different types of EC patients. The results clearly show the differential profiles of gut microbiota between EC patients and normal participants as well as the association between gut microbiota and EC progression. Targeted metabolomics of plasma revealed an increased level of C16:1 and C20:2, which was positively associated with the abundance of Ruminococcus sp. N15.MGS-57. The higher richness of Ruminococcus sp. N15.MGS-57 in EC subjects not only was positively associated with blood C16:1 and C20:2 but also was negatively correlated with betalain and indole alkaloid biosynthesis. Furthermore, the combined marker panel of gut bacteria, blood metabolites, and clinical indices could distinguish the EC patients under lean and overweight conditions from normal subjects with high accuracy in both discovery and validation sets. In addition, the alteration of tumor microenvironment metabolism of EC was characterized by imaging mass microscopy. Spatial visualization of fatty acids showed that C16:1 and C18:1 obviously accumulate in tumor tissue, and C16:1 may promote EC cell invasion and metastasis through mTOR signaling. The aberrant fecal microbiome, more specifically, Ruminococcus sp. N15.MGS-57 and spatially distributed C16:1 in EC tissues, can be used as a biomarker of clinical features and outcomes and provide a new therapeutic target for clinical treatment. IMPORTANCE A growing number of studies have shown the connection between gut microbiota, obesity, and cancer. However, to our knowledge, the association between gut microbiota and endometrial cancer progression in humans has not been studied. We recruited EC and control individuals as research participants and further subgrouped subjects by body mass index to examine the association between gut microbiota, metabolites, and clinical indices. The higher richness of Ruminococcus sp. N15.MGS-57 in EC subjects was not only positively associated with blood C16:1 but also negatively correlated with betalain and indole alkaloid biosynthesis. Spatial visualization of fatty acids by imaging mass microscopy showed that C16:1 obviously accumulates in tumor tissue, and C16:1 may promote the EC cell invasion and metastasis through mTOR signaling. The aberrant fecal microbiome, more specifically, Ruminococcus sp. N15.MGS-57 and spatially distributed C16:1, can be used as a biomarker of clinical features and outcomes and provide a new therapeutic target for clinical treatment.
Collapse
Affiliation(s)
- Shan-Shan Zhao
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province, People’s Republic of China
| | - Lei Chen
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| | - Jing Yang
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| | - Zhen-Hua Wu
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| | - Xiao-Yu Wang
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| | - Qi Zhang
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| | - Wen-Jie Liu
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| | - Hui-Xin Liu
- Health Sciences Institute, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- School of Life Sciences, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
- Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, Liaoning Province, People’s Republic of China
| |
Collapse
|
|
5
|
Yang J, Chen L, Shang XY, Chen YL, Zhao SS, Jin S, Yang J, Liu HX, Du J. Roux-en-Y gastric bypass-induced perturbative changes in microbial communities and metabolic pathways in rats. Front Microbiol 2022; 13:1034839. [DOI: 10.3389/fmicb.2022.1034839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Accepted: 10/07/2022] [Indexed: 11/11/2022] Open
Abstract
BackgroundObesity has become a global health and socioeconomic problem because of an inadequate balance between energy intake and energy expenditure. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the two most commonly used strategies for weight loss, which have been proven to benefit from gut microbiota restoration.MethodsRats received SG, RYGB, and sham operations for 10 weeks. At the end of the experiment, the fecal microbiota was analyzed using 16s rRNA gene sequencing. In addition, the shift in the plasma metabolism of rats that underwent RYGB surgery was analyzed using untargeted metabolomics. The crosstalk between microbiome and metabolites was revealed using metabolic pathway enrichment and integrated analysis.ResultThe SG surgery induced a modest shift in the gut microbiota relative to the RYGB. RYGB significantly decreased the alpha diversity and Firmicutes/Bacteroides (F/B) ratio and increased the proportion of Escherichia, Bacteroides, and Akkermansia genera compared to sham and SG operations. The predicted function of gut microbiota revealed that the RYGB surgery uniquely enhanced the capability of linoleic acid and sphingolipid metabolism. Furthermore, the circulating serine, phosphatidylcholine (PC) 20:5/22:5, riboflavin, L–carnitine, and linoleic acid were evaluated after RYGB surgery. In addition, the metabolic pathway enrichment and integrated analysis suggest that the RYGB induced Escherichia, Bacteroides, and Akkermansia might inhibit the sphingonine and phytosphingosine metabolisms from serine and promote the PC (20:5/22:5) metabolism to produce linoleic acid.ConclusionThis comprehensive analysis not only revealed the difference in the gut microbiota shifts after SG and RYGB but also discovered the perturbative changes in microbial communities and metabolic pathways after RYGB surgery, which provided clues for improving the beneficial effect of RYGB in metabolic disease intervention via regulating bacterial-metabolite crosstalk.
Collapse
|